Familial Hypercholesterolemia Clinical Trials

Find Familial Hypercholesterolemia Clinical Trials Near You

Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Participants (Age 12 to <18 Years) With Homozygous Familial Hypercholesterolemia (SPRUCE)

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This study will evaluate the efficacy and safety of zodasiran subcutaneous (sc) injection in participants 12 to \<18 years of age with genetically or clinically diagnosed homozygous familial hypercholesterolemia (HoFH) and low-density lipoprotein cholesterol (LDL-C) ≥116 milligrams per deciliter (mg/dL) on maximally tolerated lipid-lowering therapy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 17
Healthy Volunteers: f
View:

• Adolescents 12 to \<18 years of age who are nonpregnant, nonlactating, and do not plan to become pregnant during the study

• Body weight ≥35 kilograms (kg) at screening

• HoFH based on a supportive genetic test (from a source-verifiable medical record or based on screening genotype) or clinical diagnosis

• Screening LDL-C ≥116 mg/dL (3 mmol/L)

• Screening hemoglobin A1c (HbA1c) ≤9.5%

• Total bilirubin \<2×upper limit of normal (ULN), unless in previously confirmed cases of Gilbert's syndrome

• Alanine aminotransferase or aspartate aminotransferase \<3×ULN

Locations
United States
Missouri
Research Site
RECRUITING
St Louis
Other Locations
Denmark
Research Site
RECRUITING
Viborg
Poland
Research Site
RECRUITING
Warsaw
Contact Information
Primary
Medical Monitor
SPRUCE@arrowheadpharma.com
626-304-3400
Time Frame
Start Date: 2026-10
Estimated Completion Date: 2028-08
Participants
Target number of participants: 10
Treatments
Experimental: Zodasiran
Sponsors
Leads: Arrowhead Pharmaceuticals

This content was sourced from clinicaltrials.gov